Drugs for Bugs: The Next Generation of Pharmaceuticals
|
|
- Anabel Stafford
- 6 years ago
- Views:
Transcription
1
2 Drugs for Bugs: The Next Generation of Pharmaceuticals Mark Pimentel, MD, FRCP(C) Executive Director, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center
3 Microbiome The microbiome can t cause everything Patients
4 How to Treat the Microbiome? Antibiotics Kill or inhibit bacteria Probiotics Replace a deficiency of one or more bacteria Take advantage of a benefit provided by certain bacteria Fecal microbial transplant (FMT) Who is normal? Genetically engineered bacteria Produce a product that can treat human disease or promote health Drugs for bugs Not meant to kill but rather affect the production pathways of bacteria
5 Bugs as Drugs A. Probiotics - Finding bacteria that naturally produce something that is beneficial (e.g. anti-inflammatory) - Finding bacteria or sets of bacteria that restore balance Pros Simple Promising basic science Cons No magic bullets yet FDA hurdles Too many products
6 What Probiotic Should I Use? 64 different probiotics listed Refridgerated/dessicated $
7 Some of the Benefits Bifidobacter Reduces TNF Enhances mucosal IL-10 (anti-inflam) Diminishes LPS Affects toll receptors Inhibits pathogenic bacteria Improves epithelial tight junctions Promotes MMC s Increased acetate production Inhibits biofilm production Increases CD4+ T cells Decrease CD4+/CD8+ cells Many other effects
8 Bugs as Drugs B. Fecal Transplant -Replacing the whole gut microbiome Pros Simple Very promising (e.g. C diff) Cons Complications FDA hurdles What is normal feces?
9 SER-109 Not FMT but a cocktail of spores isolated from normal human stool To establish normal flora in the treatment of recurrent C. difficile infection Then 2016 happened
10 Bugs as Drugs C. Genetically modified bacteria -Contains desired gene (eg anti-tnf biologic) -Also needs kill switch Pros Simple Very promising (e.g. C diff) -Incorporates in gut microbiome to produce product (absorbed or local) Cons Complications FDA hurdles What is normal feces?
11 Kill Switches 1. Deficiency Switch Probiotic Beneficial Product/effect AA Engineered such that cannot produce an essential amino acid
12 Kill Switches 2. Deadman Switch Probiotic Toxin Beneficial Product/effect Inhibitor Blocks the production of toxin
13 Kill Switches 3. Passcode Switch Probiotic Toxin Beneficial Product/effect Multiple agents Very complex because its like a combination lock All the agents need to be there or the bacteria dies Benefit: Hard to imagine the environment might figure it out and all the bacterium escape
14 Elafin Producing Bacteria ViThera Pharmaceuticals developing VT301 for Crohn s disease Engineered Lactococcus lactis and lactobacillus caseii to produce elafin Elafin is a protease inhibitor that is produced by normal human epithelium and deactivates elastase and proteinase-3 In IBD elafin is reduced and this could allow elastase and proteinase to damage the gut wall Success in animal models Motta JP, et al. Sci Transl Medicine, 2012
15 Bacterial Injection Injecting solid tumor with bacteria Strong quorum sensing Bacteria are microaerophilic so die when in oxygen so stay in blood starved tumor Bacteria draws inflammation and kill of tumor cells Zheng, et al. Sci Translat Med, 2017
16 Protecting Good Bugs iv antibiotics Gut penetration Beta lactamase SYN-004 Pros Simple Proven effective Cons B-lactams only
17 Why is Rifaximin a Microbiome Drug? 1. Not systemic 2. Soluble in bile in small bowel, precipitates in the colon 3. Works only in the small bowel 4. No yeast accumulation 5. 98% of stool flora unchanged after 3 courses of rifaximin 6. No development of bacterial resistance Kim, et al. Dig Dis Sci 2013 Pimentel, et al. Dig Dis Sci 2017
18 TARGET 1 and 2 Trials for IBS Primary Primary Efficacy Outcome Efficacy Outcome SGA-IBS Weekly SGA-IBS Weekly Study TARGET Study TARGET 1 TARGET TARGET 2 Odds Odds Ratio Ratio (95% CI) p-value (1.10,2.12) (95% CI) p-value (1.10,2.12) (1.05,2.01) (1.05,2.01) (1.18,1.88) (1.18,1.88) Key Key Secondary Secondary IBS Bloating Weekly IBS Bloating Weekly TARGET TARGET 1 TARGET TARGET (1.16,2.27) (1.16,2.27) (1.08,2.06) (1.08,2.06) (1.23,1.96) (1.23,1.96) Other Other Secondary Secondary SGA-IBS Daily SGA-IBS Daily IBS Bloating IBS Bloating Daily Daily IBS Ab Pain IBS Ab Pain Daily Daily TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET (1.26,2.47) (1.26,2.47) (1.13,2.24) (1.28,2.04) (1.13,2.24) (1.28,2.04) (1.01,1.97) (1.01,1.97) (1.26,2.44) (1.26,2.44) (1.21,1.92) (1.21,1.92) (1.05,2.02) (1.05,2.02) (1.05,2.03) (1.05,2.03) (1.13,1.78) (1.13,1.78) < < FDA FDA Proposed Proposed Ab Pain Stool Ab Pain & Stool Daily (FDA) Daily (FDA) Ab Pain Daily Ab Pain Daily (FDA) (FDA) Stool Consist. Stool Consist. Daily (FDA) Daily (FDA) TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET (1.02,1.92) (1.02,1.92) (1.12,2.13) (1.12,2.13) (1.17,1.84) (1.17,1.84) (1.08,2.03) (1.08,2.03) (1.06,2.00) (1.17,1.83) (1.06,2.00) (1.17,1.83) (1.25,2.59) (1.25,2.59) (1.12,2.21) (1.12,2.21) (1.31,2.14) (1.31,2.14) < < Pimentel, et al NEJM, Odds Ratio and 95% CI Odds Ratio and 95% CI Favors Placebo Favors Rifaximin Favors Placebo Favors Rifaximin
19 TARGET 1 and 2 Durable IBS Response Primary Efficacy Outcome SGA-IBS Weekly Study TARGET 1 TARGET 2 Odds Ratio (95% CI) (1.00, 1.82) (1.13, 2.03) (1.17, 1.77) p-value Key Secondary IBS Bloating Weekly TARGET 1 TARGET (0.95, 1.73) (1.16, 2.09) (1.15, 1.75) Other Secondary SGA-IBS Daily IBS Bloating Daily IBS Ab Pain Daily TARGET 1 TARGET 2 TARGET 1 TARGET 2 TARGET 1 TARGET (1.18, 2.18) (1.09, 1.99) (1.20, 1.83) (1.10, 2.04) (1.24, 2.25) (1.24, 1.89) (1.00, 1.83) (1.01, 1.81) (1.06, 1.61) < FDA Proposed Ab Pain & Stool Daily (FDA) Ab Pain Daily (FDA) Stool Consist. Daily (FDA) TARGET 1 TARGET 2 TARGET 1 TARGET 2 TARGET 1 TARGET (1.01, 1.83) (1.08, 1.92) (1.14, 1.72) (0.98, 1.75) (1.03, 1.83) (1.09, 1.64) (1.24, 2.33) (1.09, 2.00) (1.27, 1.97) < Odds Ratio and 95% CI Pimentel, et al NEJM, 2011 Favors Placebo Favors Rifaximin
20 Effect of Rifaximin (10 years later) Increasing rifaximin use 40% reduction in D-IBS Oh SJ, et al DDW 2017
21 Drugs for Bugs -Proteins -Gases -Toxins -Adhesins -Flagellae -Sterols -Obesity -IBS -IBD -Constipation -Others Block pathway for these human harmful byproducts Pros Simple Very promising (e.g. C diff) Cons Complications FDA hurdles What is normal feces?
22 Non-Antibiotic Drugs Block adhesion (Prevent retention) Dozens of products that could affect host
23 Statins and Methane Lovastatin was later discovered from Aspergillus spp Akiro Endo (1971) discovered mevastatin which is a chemical produced by certain fungi to defend against other organisms Mevastatin was toxic to humans
24 How Lovastatin Would Help Hydrogen (H 2 ) Lovastatin Syntroph F420 Methane (CH 4 ) M. smithii F420 is the key enzyme in path that makes methane in M. smithii
25 Lovastatin Lactone and F420 Enzyme Muskal SM, et al. F ;5:606.
26 Lovastatin Timed Release Phase 2 Trial Study 1 Study 2 SYN mg (19) SYN mg (54) CH 4 >10 ppm SYN mg (22) Placebo (22) Subjects who successfully completed Study 1 were transferred to active drug at Day 29 Screen Day Gottlieb K, et al. DDW Lactulose breath test (LBT)
27 Breath Methane AUC at Week 12 (ppm*h) Methane Correlates with Improved Symptoms on Lovastatin p = Gottlieb K, et al. DDW Weekly No. Complete Spontaneous Bowel Movements (CSBMs)
28 Clinical Responders by Month Month Month Month Month Dose Month 1 Dose Months 2,3 Gottlieb K, et al. DDW 2016.
29 No. Subjects Using Rescue Medication % Subjects Using Rescue Medication in Study Lovastatin Timed Release Daily use of RLax (bisacodyl; 5 mg) Placebo SYN mg SYN mg in Study Study Day 100% % Subjects using RLax (bisacodyl; 5 mg) 90% 80% 70% 60% 50% 40% 30% 20% 10% % in Study % *p=0.013 vs Placebo p=0.03 vs Placebo Fisher s exact test 21.1% Placebo SYN mg SYN mg Gottlieb K, et al. DDW 2016.
30 Company Product Indication Stool Open biome Stool CDI RBX2660 Rebiotix Purified stool bacteria CDI, IBD MET-1 Nubiyota 33 bacteria probiotic CDI SER-109 Seres Spores to re-establish flora CDI SER-287 Seres Spores IBD VE-202 Vedanta Clostridium that restores IBD CBM-588 Osel Clostridium butyricum CDI, IBD L plantarum Optibiotix L plantarum Obesity CNDO-201 Fortress Trichuris suis Crohns Blautix 4D pharma Bacterial blend IBS Thetanix - Anti-inflam protein from bacteroides IBD AG-014 Intrexon Genetic modified lactobac secreting anti-inflam chemicals IBD SHP-01 Symbiotic Lysin antimicrobial enzyme CDI VT-301 ViThera Elafin producing lactobacillus IBD SGM nd Genome Molecule inhibits host microbe interaction IBD SYN-004 Synthetic Biologics Β-lactamase CDI prevent SYN-010 Synthetic Biologics Block methane production Constip Rifaximin Salix Gut specific microbial modulator D-IBS Early phase Failing Phase II+ Approved
31 Conclusion 1. There are emerging therapeutics directed at the gut microbiome to treat human disease 2. Most are using bugs as drugs 3. Future therapies will include drugs for bugs 4. There needs to be an increased tolerance load for investment in this area of work
APDW 2016 Poster No. a90312
APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,
More informationGut Microbes: Systemic Disease. Mark Pimentel, MD. Cedars-Sinai Medical Center. Mark Pimentel, MD, FACG
Gut Microbes: Role in Health, IBS, GI and Systemic Disease Mark Pimentel, MD Director, GI Motility Program Cedars-Sinai Medical Center 1 Lacks cellulase cannot breakdown cellulose Depends completely on
More informationROLE OF THE GUT BACTERIA
ROLE OF THE GUT BACTERIA Our Good Bacteria In a perfect world, we would all have a proper ratio of good bacteria And what could this proper ratio do for us? The knowledge of the connections between our
More informationNew Developments in Irritable Bowel Syndrome
New Developments in Irritable Bowel Syndrome Mark Pimentel, MD, FRCP(C) Director, GI Motility Program Cedars-Sinai Medical Center IBS Forks in the Road Not all decisions in how to handle IBS made things
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationUnderstanding probiotics and health
Understanding probiotics and health Gemma Laws MSc Student Microbiology and Immunology Department The gut microbiota The name given to the total microbial population living in our intestine Bacteria, fungi,
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationWhat Are Probiotics? PROBIOTICS
PROBIOTICS What Are Probiotics? Probiotics are living, microscopic (very small) organisms that can help your gut health. Most often, probiotics are bacteria, but they may also be other organisms, such
More informationMicrobiome in You: Optimizing Gut Bacteria for Better IBD Management
Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School
More informationDisarming C. diff bacteria without destroying healthy gut flora
Disarming C. diff bacteria without destroying healthy gut flora Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug
More informationThe Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012
The Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012 Microbes are all over us Page 1 of 22 There are millions of microbes per square inch on your body Thousands of different species on
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationHompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation
Hompes Method Practitioner Training Level II Lesson Seven Part A DRG Pathogen Plus Interpretation Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of
More informationStool Testing for the Microbiome - Ready for Primetime?
Stool Testing for the Microbiome - Ready for Primetime? Gillian M. Barlow, PhD Project Scientist, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center Take Charge of
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More informationThe effect of probiotics on animal health: a focus on host s natural intestinal defenses
The effect of probiotics on animal health: a focus on host s natural intestinal defenses Guillaume Tabouret Animal Health Dept. Joint Unit 1225 Host Pathogens Interactions History of probiotics and definition
More informationCorporate Overview. August Leading the Microbiome Revolution
Corporate Overview August 2018 Leading the Microbiome Revolution Forward looking statements Some of the statements in this presentation constitute forward looking statements under the Private Securities
More informationFecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report
Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Qiurong Li Institute of General Surgery, Jinling Hospital Nanjing Univeristy Gut Microbiota 100 trillion cells 10-fold of
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationFecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,
More informationDysbiosis & Inflammation
MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological
More informationConsistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile
Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis Courtney Jones, BS Rebiotix Inc. Roseville, MN USA
More informationProbiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017
Probiotics: Their Role in Medicine Today Viki Barr Pharm.D., BCPS AQ ID Assistant Professor, Pharmacy Practice Rosalind Franklin University of Medicine and Science Clinical Pharmacist, Infectious Diseases
More informationIncreasing barrier function with multispecies probiotics
Increasing barrier function with multispecies probiotics Elsbeth Pekelharing, MSc Science Liaison We strive for the most effective microbiome management solutions with our evidence-based & indication-specific
More informationHOW THE MICROBIOME AFFECTS OUR HEALTH
HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins
More information4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures
GI MICROBIOME & HEALTH: A REVIEW Nancy C. Kois, MD, FCAP Contemporary Pathology Services DISCLOSURES There are no disclosures OBJECTIVES Definitions: GI microbiota, GI microbiome, probiotic, prebiotic
More informationAUTOIMMUNITY AND THE GUT
AUTOIMMUNITY AND THE GUT Autoimmunity The Past The rationale - All about a malfunctioning immune system The immune system is overactive to the point of attacking the body Avoid anything that stimulates
More informationWhat are probiotics? How do probiotics benefit health?
The culture club So, you re clean eating, gluten free, fasting, eating avocados like their going out of fashion, chugging down green juices with the latest wonder powders and using coconut oil to cook
More informationMicrobiome. A new dimension in Medicine. Israel De Alba, MD MPH. Clinical Professor
Microbiome A new dimension in Medicine Israel De Alba, MD MPH Clinical Professor AIM To look at ordinary things from a different perspective.to jump start curiosity Reason to have lunch We know so much
More informationFECAL TRANSPLANTATION
FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome
More informationFaecalibacterium prausnitzii
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:
More information1. BACKGROUND. Lovastatin β-hydroxyacid No effect on methane production Inhibits cholesterol synthesis
1. BACKGRUND Methane production by the archeon Methanobrevibacter smithii (M. smithii) is a ubiquitous process in the intestine, disposing of hydrogen and other by-products formed during carbohydrate digestion
More informationBacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology
More informationSIBO
SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not
More informationEver wonder what s really happening on the inside?
For Practitioners Ever wonder what s really happening on the inside? Are your patients suffering from diarrhea, constipation, bloating, gas or indigestion? Rocky Mountain Analytical is now offering Gut-Well
More informationE. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications. Sudesh Samuel Scientific Director Amber Laboratories
E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications Sudesh Samuel Scientific Director Amber Laboratories Content E. coli s background Gut Microbiome Pathogenic E. coli Probiotic
More informationLaboratory report. Test: Leaky gut test. Sample material: stool. John Doe Main St 1 Anytown
1 / 5 Verisana LAB John Doe Main St 1 Anytown Surname, First name Doe, John DOB 02/13/1980 Sex male Laboratory # 20020181 Date collected 01/25/2018 Date received 02/01/2018 Report date 02/13/2018 Laboratory
More information2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal
PROBIOTICS LEARNING THE WHY AND WHEN PROBIOTICS DEFINITION live micro-organisms organisms that are beneficial to the host organism WHO: Live organisms which, when administered in adequate amounts, confer
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationModule Four: The GI System Module Five: The Gut Microbiome. The GI System. LLiana Shanti, CN
Module Four: The GI System Module Five: The Gut Microbiome The GI System LLiana Shanti, CN www.healthmasteryinstitute.com Review Review Review The Gut Hippocrates has been quoted as saying death sits in
More informationPennington Feb 19, 2015
Trust your gut Pennington Feb 19, 2015 Crohn s Disease -an autoimmune disorder that causes inflammation of the intestinal tract along with unpredictable, often incapacitating episodes of abdominal pain
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationThe good, the bad and the ugly. Our microbiome and it s effect on health and disease.
The good, the bad and the ugly Our microbiome and it s effect on health and disease. Objectives Discuss C difficile infection including treatment options Explain process of Fecal MicrobiotaTransplantation
More informationFunctional Nutrition Approaches to Gut Health 20 CPEU Module accredited by Nutrition Mission
Topics Covered 1. Good Health Starts in the Gut 2. Microbiome Part 1 3. Microbiome Part 2 4. What Can Go Wrong 5. FODMAP Intolerance 6. GERD 7. Celiac Disease 8. Non-Celiac Gluten Sensitivity 9. Intestinal
More informationRegulatory challenges in the drug-food continuum. Yolanda Sanz IMI Stakeholder Forum Microbiome Brussels, Belgium
Regulatory challenges in the drug-food continuum Yolanda Sanz 19.10.2017 IMI Stakeholder Forum Microbiome Brussels, Belgium Outline Regulation of health claims on foods EU No 1924/2006 Reconciling science
More informationTreatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department
Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of
More informationCurrent Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics. Deborah Cook
Current Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics Deborah Cook Objectives VAP The Old: Gastropulmonary route of infection The New: Microbiome modification Role of acid suppression Influence
More informationManipulating the gut microbiome
Manipulating the gut microbiome William DePaolo, PhD Associate Professor Medicine Director Center for Microbiome Sciences & Therapeutics University of Washington Microbiota The actual bugs that reside
More information!Microbiology Profile, stool
LAB #: F000000-0000-0 PATIENT: Sample Patient ID: P12345 SEX: Female AGE: 37 CLIENT #: 12345 DOCTOR: Doctor's Data, Inc. 3755 Illinois Ave. St. Charles, IL 60174!Microbiology Profile, stool BACTERIOLOGY
More informationWhen To Do Fecal Microbiota Transplant (FMT) For C. difficile
When To Do Fecal Microbiota Transplant (FMT) For C. difficile Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationFecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohn's Disease
Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohn's Disease March 2015 - Volume 21 - Issue 3 - p 556 563 doi: 10.1097/MIB.0000000000000307 Original Clinical Articles
More informationCorporate Medical Policy
Corporate Medical Policy Fecal Analysis in the Diagnosis of Intestinal Dysbiosis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: fecal_analysis_for_intestinal_dysbiosis 5/2001 5/2018
More informationDiverticular Disease: Looking beyond fiber
Binghamton University The Open Repository @ Binghamton (The ORB) Health & Wellness Studies Faculty Scholarship Decker School of Nursing Fall 10-28-2015 Diverticular Disease: Looking beyond fiber Lina Begdache
More informationNYSE MKT: SYN. FBR & Co. 2 nd Annual Healthcare Conference
NYSE MKT: SYN FBR & Co. 2 nd Annual Healthcare Conference Boston, MA September 9, 2015 Forward-Looking Statements This presentation includes forward-looking statements on Synthetic Biologics current expectations
More information12/1/2017. Disclosures. Objectives. The Microbiome Defined
Can Critical Illness and the Microbiome Play Nice Together? SCOTT BOLESTA, PHARMD, BCPS, FCCM ASSOCIATE PROFESSOR OF PHARMACY PRACTICE, WILKES UNIVERSITY VISITING INVESTIGATOR, GEISINGER HEALTH SYSTEM
More informationPoultry The unique probiotic
Poultry The unique probiotic Probiotics Probiotics have been defined as live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance. Achieving
More informationESPEN Congress Vienna Networking with your microbiota Specific evidence-based indications. H. Lochs (Germany)
ESPEN Congress Vienna 2009 Networking with your microbiota Specific evidence-based indications H. Lochs (Germany) Probiotics Evidence based indications H. Lochs Medizinische Klinik mit Schwerpunkt Gastroenterologie,
More information10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance
The Microbiome vs. the Gastroenterologist John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Human Microbiome Mouth Finlay BB. Scientific American 2010;302:56-63 Microbiome
More informationC. difficile: When to Do Fecal Microbiota Transplant (FMT)
C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationModule Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know
Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities & taxonomy 3. Other microbes: archaea, fungi, viruses, parasites
More informationThe Bi-Phasic SIBO Protocol Module 1 Diagnosing SIBO
Dr Nirala Jacobi, BHSc, ND Author, SIBO Bi-Phasic Treatment Protocol and the SIBO Bi-Phasic Diet Medical Director, SIBOTest.com and host of TheSIBODoctor.com The Bi-Phasic SIBO Protocol Module 1 Diagnosing
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationExosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE
Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray
More informationIrritable Bowel Syndrome Causes and Treatments
Irritable Bowel Syndrome Causes and Treatments Oh heck. Gas, bloating, alternating constipation and diarrhea, food cravings and abdominal pain. Your symptoms may be significant and cause you embarrassment
More informationThe role of the microbiome in type 2 diabetes
The role of the microbiome in type 2 diabetes Expert Forum on diabetes: Genetics, nutrition and the future of diabetes management 10 October 2017 Luc Sterkman, MD CEO Caelus Health Bugs in daily life Good
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationResearch Update: Looking for the Answers
Research Update: Looking for the Answers Ted Denson, M.D. Schubert-Martin Inflammatory Bowel Disease Center Research Support: NIH/NIDDK, CCFA, BMRP Figure 2 Approach to Improve Outcomes for our IBD Patients
More information2/13/2018. What s bugging you? Relevance of the Human Microbiome in Health and Disease Heidi H. Kong, MD, MHSc, FAAD Dermatology Branch
What s bugging you? Relevance of the Human Microbiome in Health and Disease Heidi H. Kong, MD, MHSc, FAAD Dermatology Branch DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Heidi H Kong, MD, MHSc, FAAD U017:
More informationClinical Policy Bulletin: Fecal Bacteriotherapy
Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed
More informationMegaSporeBiotics Probiotics. Linda Wilbert - Stewart, FDN, HHP, HC 1/28/
MegaSporeBiotics Probiotics www.exclusivelyholistic.com Linda Wilbert - Stewart, FDN, HHP, HC 1/28/2015 111 MegaSporeBiotic is the first, all spore, carotenoid rich, probiotic consortium formulation on
More informationgeneral meeting 1 20 October 2016
general meeting 1 20 October 2016 introductions today s topics the human microbiome about the study the human microbiome the human microbiome human microbiota: the microorganisms that live within and on
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationT H E B E T T E R H E A L T H N E W S
Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 1 3, I S S U E 4 T H E B E T T E R H E A L T H N E W S A P R I L, 2 0 1 6 M O R E P R O B L E M S W I T H P R O T O N P U M P I N H I B I
More informationGut bugs and health. Patrick Bateson
Gut bugs and health Patrick Bateson Characteristic odour of kin group is produced by inherited bacterial flora degrading fats secreted by anal glands An increasing number of people in developed countries
More informationUNDERSTANDING PROBIOTIC SUPPLEMENTS
UNDERSTANDING PROBIOTIC SUPPLEMENTS Probiotics Health Canada Definition: Probiotics are considered to be live microorganisms which, when administered in adequate amounts, confer a health benefit on the
More informationSIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.
SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello Microbiota e IBS Cesare Cremon Policlinico S. Orsola Malpighi Azienda Ospedaliero - Universitaria di
More informationThe vital role of the microbiome in human health
The vital role of the microbiome in human health abandoning hygiene is not the way to a healthy microbiome Colin Hill APC Microbiome Institute University College Cork @colinhillucc Mixed messages? We live
More informationUNDERSTANDING PROBIOTIC SUPPLEMENTS
Slide 1 UNDERSTANDING PROBIOTIC SUPPLEMENTS Slide 2 Probiotics Health Canada Definition: Probiotics are considered to be live microorganisms which, when administered in adequate amounts, confer a health
More information11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley
MICROBIOME AND THE BRAIN: How your gut impacts wellbeing Session One Sue Langley 2018 2017 Langley Group IP Trust Approach Lessons from Venice 1 Lessons from Venice Agenda 2. Implications and research
More informationSmall Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results
Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Martin Carr, M.D. March 3, 2018 Good evening everyone, this is Martin Carr, and I
More informationPigs The unique probiotic
Pigs The unique probiotic PROBIOTICS Probiotics have been defined as live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance. Achieving a
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More information1. Nutrient and calorie extraction from our foods which determines how well nourished we are - and how well we can regulate our weight
The digestive system (gut) is a tube that begins at the mouth at the top and ends at the anus. Along the way one encounters the stomach, small intestines, and large intestines. Each of these regions has
More informationCULINARY HERBS AND SPICES
CULINARY HERBS AND SPICES Using Culinary Herbs and Spices Flavour and texture are a huge issue when it comes to introducing new foods to a client Herb and spices can help make a new food seem like an old
More informationMyalgic encephalomyelitis: A highly prevalent debilitating disease
Myalgic encephalomyelitis: A highly prevalent debilitating disease Persistent, debilitating fatigue associated with numerous physical and neurocognitive symptoms Disease severity can range from moderate
More informationWhat GI Physicians Need to Know About Probiotics
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/what-gi-physicians-need-to-know-about-probiotics/3844/
More informationHMP is lead by NIH but is an International Consortium.
Human Microbiome The Human Microbiome Project was one of the spin offs of the Human Genome Project. The HMP project started in 2007 with the overall goal of Characterizing the Human Microbiome and determine
More informationThe science behind probiotics Colin Hill, APC Microbiome Institute University College Cork Ireland
The science behind probiotics Colin Hill, APC Microbiome Institute University College Cork Ireland Illustration Charis Tsevis Probiotics live microorganisms that, when administered in adequate amounts,
More informationPROBIOTICS. what they are and what they can do for you. A patient s guide from your doctor and
PROBIOTICS what they are and what they can do for you A patient s guide from your doctor and Probiotics Products containing probiotics have flooded the market in recent years. As more people seek natural
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationIs FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016
Is FMT the answer? Challenging Cases in CDI Ted Steiner, M.D. April 1, 2016 CONFLICT OF INTEREST DISCLOSURE SLIDE In the past 2 years I have been an employee of: In the past 2 years I have been a consultant
More informationHompes Method. Practitioner Training Level II. Lesson Five (a) Bad Bugs - Bacteria
Hompes Method Practitioner Training Level II Lesson Five (a) Bad Bugs - Bacteria Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of Health For The People
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More information